• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cellular biochemistry. >Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.
【24h】

Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.

机译：进行原位组织修复：人间充质干细胞表达趋化因子受体CXCR1，CXCR2和CCR2，并在受CXCL8刺激后迁移，但不向CCL2迁移。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The recruitment of bone marrow CD34- mesenchymal stem- and progenitor cells (MSC) and their subsequent differentiation into distinct tissues is the precondition for in situ tissue engineering. The objective of this study was to determine the entire chemokine receptor expression profile of human MSC and to investigate their chemotactic response to the selected chemokines CCL2, CXCL8 and CXCL12. Human MSC were isolated from iliac crest bone marrow aspirates and showed a homogeneous population presenting a typical MSC-related cell surface antigen profile (CD14-, CD34-, CD44+, CD45-, CD166+, SH-2+). The expression profile of all 18 chemokine receptors was determined by real-time PCR and immunohistochemistry. Both methods consistently demonstrated that MSC express CC, CXC, C and CX(3)C receptors. Gene expression and immunohistochemical analysis documented that MSC express chemokine receptors CCR2, CCR8, CXCR1, CXCR2 and CXCR3. A dose-dependent chemotactic activity of CXCR4 and CXCR1/CXCR2 ligands CXCL12 andCXCL8 (interleukin-8) was demonstrated using a 96-well chemotaxis assay. In contrast, the CCR2 ligand CCL2 (monocyte chemoattractant protein-1, MCP-1) did not recruited human MSC. In conclusion, we report that the chemokine receptor expression profile of human MSC is much broader than known before. Furthermore, for the first time, we demonstrate that human MSC migrate upon stimulation with CXCL8 but not CCL2. In combination with already known data on MSC recruitment and differentiation these are promising results towards in situ regenerative medicine approaches based on guiding of MSC to sites of degenerated tissues.
机译：募集骨髓CD34-间充质干细胞和祖细胞（MSC）及其随后分化为不同组织是原位组织工程的前提。这项研究的目的是确定人类MSC的完整趋化因子受体表达谱，并研究其对所选趋化因子CCL2，CXCL8和CXCL12的趋化反应。从骨骨髓抽吸物中分离出人MSC，并显示出具有典型MSC相关细胞表面抗原特征（CD14-，CD34-，CD44 +，CD45-，CD166 +，SH-2 +）的同质群体。通过实时PCR和免疫组织化学确定所有18种趋化因子受体的表达谱。两种方法一致证明MSC表达CC，CXC，C和CX（3）C受体。基因表达和免疫组织化学分析表明，MSC表达趋化因子受体CCR2，CCR8，CXCR1，CXCR2和CXCR3。使用96孔趋化性试验证明了CXCR4和CXCR1 / CXCR2配体CXCL12和CXCL8（白介素8）的剂量依赖性趋化活性。相反，CCR2配体CCL2（单核细胞趋化蛋白-1，MCP-1）没有募集人MSC。总之，我们报道了人MSC的趋化因子受体表达谱比以前已知的广泛得多。此外，我们首次证明了人类MSC在受CXCL8刺激后迁移，但没有CCL2刺激。与有关MSC募集和分化的已知数据相结合，这些都是基于将MSC引导至变性组织部位的原位再生医学方法的有希望的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号